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**Abstract**

The current nomenclature of drugs used for mania and psychosis is based on clinical indications; they are classified as "mood stabilizers" and "antipsychotic drugs", respectively. While this conventional nomenclature has been widely used in clinical as well as research settings, there are a number of limitations to this system. First, boundaries among various categories of psychotropic drugs, using the current nomenclature have become unclear. "Antipsychotic drugs" and "mood stabilizers" are good examples; antipsychotic drugs are used for not only schizophrenia, but also mood disorders, including bipolar disorder and treatment resistant depression. On the other hand, mood stabilizers are often prescribed for a mood component in any psychiatric disorder. This discrepancy between their names and indications often confuses patients and their caregivers and sometimes leads to a misunderstanding of the effects of prescribed medications. This misunderstanding could have negative consequences on medication adherence. Second, up-to-date scientific knowledge on these drugs has not been reflected in the current nomenclature. This is a serious issue since the current system was created nearly half a century ago. For example, dopamine receptor antagonists and a partial dopamine receptor agonist are currently included in the same category of "antipsychotic drugs" despite the difference in their drug profiles. Moreover, the involvement of the serotonergic system also has to be considered for some drugs. However, such differences are not reflected in the current system. Third, unique and sometimes catchy labeling of particular drugs such as multi-acting receptor targeted antipsychotics (MARTA), serotonin dopamine antagonist (SDA), and dopamine system stabilizer (DSS), are proposed and initiated by pharmaceutical companies and often well accepted; however, they do not always accurately describe the mechanisms of action of those drugs. To overcome these limitations of the current nomenclature, the neuroscience-based nomenclature (NbN) was developed, which reflects our current neuroscience advances in a scientifically sound classification system. Antipsychotic drugs and mood stabilizers are now classified under the categories of "drugs used for psychosis" and "drugs for relapse prevention", respectively. Moreover, within each category, drugs are classified based on their pharmacological profiles. So far, 26 drugs used for psychosis and 5 drugs for relapse prevention have been included, and more drugs will be added in the future. In this presentation, examples of multidimensional classification with respect to medications used for the treatment of psychosis and mania will be presented.
